Renaissance Technologies LLC Boosts Holdings in Cellebrite DI Ltd. (NASDAQ:CLBT)

Renaissance Technologies LLC increased its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 7.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,630,439 shares of the company's stock after acquiring an additional 115,939 shares during the quarter. Renaissance Technologies LLC owned about 0.79% of Cellebrite DI worth $35,919,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also made changes to their positions in the company. FMR LLC raised its position in Cellebrite DI by 89.1% in the 4th quarter. FMR LLC now owns 10,621,344 shares of the company's stock worth $233,988,000 after buying an additional 5,004,587 shares during the last quarter. True Wind Capital Management L.P. boosted its stake in shares of Cellebrite DI by 18.2% during the 4th quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company's stock worth $305,358,000 after acquiring an additional 2,130,386 shares during the last quarter. Invesco Ltd. bought a new stake in shares of Cellebrite DI during the 4th quarter valued at $32,700,000. Principal Financial Group Inc. bought a new position in Cellebrite DI in the 3rd quarter worth $23,402,000. Finally, Lord Abbett & CO. LLC bought a new position in Cellebrite DI in the 3rd quarter worth $11,523,000. Institutional investors own 45.88% of the company's stock.

Cellebrite DI Stock Down 1.6 %

CLBT stock traded down $0.31 during mid-day trading on Wednesday, hitting $19.03. The company had a trading volume of 649,080 shares, compared to its average volume of 1,398,663. The company has a market capitalization of $4.56 billion, a price-to-earnings ratio of -13.69, a P/E/G ratio of 4.27 and a beta of 1.44. The company has a 50-day moving average price of $19.36 and a 200 day moving average price of $20.03. Cellebrite DI Ltd. has a 12-month low of $10.25 and a 12-month high of $26.30.

Remove Ads

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. As a group, analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on CLBT shares. Lake Street Capital upped their price target on Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a research report on Friday, February 14th. JPMorgan Chase & Co. raised their target price on shares of Cellebrite DI from $24.00 to $28.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 11th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $28.00 price target on shares of Cellebrite DI in a research report on Wednesday, April 2nd. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $23.43.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.